SELB - セレクタ・バイオサイエンシズ （Selecta Biosciences Inc.）

Selecta Biosciences (NASDAQ:SELB – Get Rating) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday. Several other research firms have also weighed in on SELB. Mizuho cut their target price on Selecta Biosciences from $5.00 to $4.00 and set a […]

Selecta Biosciences, Inc. (NASDAQ:NASDAQ:SELB) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ETCompany ParticipantsBlaine Davis - CFOCarsten Brunn - CEO, President &…

Selecta Biosciences press release (SELB): Q1 GAAP EPS of -$0.14 misses by $0.05.Revenue of $5.9M (-82.6% Y/Y) misses by $6.24M.$127.5 million in cash, cash equivalents, restricted…

Selecta Biosciences (SELB) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open.The consensus EPS Estimate is -$0.09 and the consensus Revenue Estimate is…

WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, May 4, 2023, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2023 and provide a business update.

WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, May 4, 2023, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2023 and provide a business update.

https://www.investing.com/news/pro/selecta-biosciences-pt-raised-to-5-at-hc-wainwright-432SI-3037560

Shares of biopharmaceutical company Selecta Biosciences (NASDAQ:CELB) are trending today after it announced positive topline results from a Phase 3…

NEW YORK , March 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SELB, ONON, EMAN, HLIT, and CSIQ. … Full story available on Benzinga.com

Selecta Biosciences (SELB) and Swedish Orphan Biovitrum (Sobi) (BIOVF) said SEL-212 met the main goals of two phase 3 trials to treat adult patients with chronic refractory gout.Gout is…

NEW YORK , June 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUVI, NIO, WEJO, HSDT, and SELB. … Full story available on Benzinga.com

The trading price of Selecta Biosciences Inc. (NASDAQ:SELB) closed higher on Tuesday, May 31, closing at $0.88, 14.96% higher than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $0.7801 … Selecta Biosciences Inc. (NASDAQ: SELB) Stock: Can Value Hunters Buy It? Read More »

In the last trading session, 2.14 million shares of the Selecta Biosciences Inc. (NASDAQ:SELB) were traded, and its beta was 1.36. Most recently the company’s share price was $0.77, and it changed around $0.07 or 9.38% from the last close, which brings the market valuation of the company to $106.55M. SELB currently trades at a … Let’s Talk About How Selecta Biosciences Inc. (NASDAQ: SELB) Stock Is Doing. Read More »

In the last trading session, 1.89 million Selecta Biosciences Inc. (NASDAQ:SELB) shares changed hands as the company’s beta touched 1.30. With the company’s per share price at $0.80 changed hands at $0.03 or 2.76% during last session, the market valuation stood at $117.57M. SELB’s last price was a discount, traded about -560.0% off its 52-week … Selecta Biosciences Inc. (NASDAQ: SELB) Stock Forecast For 2022: Increases Growth Prospects To $9 Per Share Read More »

This article covers seven cheap biotech stocks for investors with a high risk tolerance. ImmunityBio ( IBRX ): Boasts an extensive pipeline that covers multiple chronic conditions. Selecta Biosciences ( SELB ): Clinical-stage biotech with truckloads of cash to take its novel immune tolerance platform past the finish line. Bluebird Bio ( BLUE ): Speculative biotech with a colossal growth runway if the FDA gives its gene therapies the green light. Vistagen Therapeutics ( VTGN ): Unique portfolio of therapeutics which target the nervous system in an industry set for tremendous growth ahead. BioNano Genomics Inc ( BNGO ): This meme stock could develop a long-term recurring revenue-generating machine with its genome image editing tool. Verastem ( VSTM ): This startup develops novel cancer treatments with the goal of delivering the best-in-class RAS pathway product. BioCryst Pharmaceuticals ( BCRX ): Biotech with a robust rare disease drug portfolio and strong liquidity. Source: Mongkolchon Akesin / Shutterstock.com Amidst immense market volatility, investors favor value-oriented sectors to minimize risk.